Literature DB >> 3020819

The quest for a herpes simplex virus vaccine: background and recent developments.

M J Hall, K Katrak.   

Abstract

Herpes simplex virus infections in humans range from localized skin infections of the oral, ocular and genital regions, to severe and often fatal disseminated infections of immunocompromised hosts. Following primary infection, the virus often becomes established in a latent form in the neurons of sensory ganglia and can reactivate to excrete virus asymptomatically or produce recrudescent lesions. This review describes some of the mechanisms involved in the immune response against HSV infections and examines the different strategies adopted to develop a vaccine against this seemingly intractable disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3020819     DOI: 10.1016/0264-410x(86)90001-0

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Analogues of peptide 9-21 of glycoprotein D of herpes simplex virus and their binding to group VII monoclonal antibodies.

Authors:  S Welling-Wester; M Feijlbrief; D G Koedijk; J W Drijfhout; W J Weijer; A J Scheffer; G W Welling
Journal:  Arch Virol       Date:  1994       Impact factor: 2.574

2.  Antibodies against synthetic peptides of herpes simplex virus type 1 glycoprotein D and their capability to neutralize viral infectivity in vitro.

Authors:  W J Weijer; J W Drijfhout; H J Geerligs; W Bloemhoff; M Feijlbrief; C A Bos; P Hoogerhout; K E Kerling; T Popken-Boer; K Slopsema
Journal:  J Virol       Date:  1988-02       Impact factor: 5.103

3.  Expression of cell-associated and secreted forms of herpes simplex virus type 1 glycoprotein gB in mammalian cells.

Authors:  C Pachl; R L Burke; L L Stuve; L Sanchez-Pescador; G Van Nest; F Masiarz; D Dina
Journal:  J Virol       Date:  1987-02       Impact factor: 5.103

4.  Escherichia coli-derived envelope protein gD but not gC antigens of herpes simplex virus protect mice against a lethal challenge with HSV-1 and HSV-2.

Authors:  M Bröker; K J Abel; R Köhler; J Hilfenhaus; E Amann
Journal:  Med Microbiol Immunol       Date:  1990       Impact factor: 3.402

Review 5.  Recent progress in herpes simplex virus immunobiology and vaccine research.

Authors:  David M Koelle; Lawrence Corey
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

6.  T cell responses to synthetic peptides of herpes simplex virus type 1 glycoprotein D in naturally infected individuals.

Authors:  R A Damhof; J W Drijfhout; A J Scheffer; J B Wilterdink; G W Welling; S Welling-Wester
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

7.  Viral encephalitis in England, 1989-1998: what did we miss?

Authors:  Katy L Davison; Natasha S Crowcroft; Mary E Ramsay; David W G Brown; Nick J Andrews
Journal:  Emerg Infect Dis       Date:  2003-02       Impact factor: 6.883

Review 8.  Developments in herpes simplex virus vaccines: old problems and new challenges.

Authors:  J Rajcáni; V Durmanová
Journal:  Folia Microbiol (Praha)       Date:  2006       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.